MAIA Biotechnology, Inc. (MAIA)

NYSEAMERICAN: MAIA · IEX Real-Time Price · USD
4.57
-0.16 (-3.38%)
Feb 6, 2023, 1:44 PM EST - Market open
-3.38%
Market Cap 50.02M
Revenue (ttm) n/a
Net Income (ttm) -15.09M
Shares Out 10.95M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,143
Open 4.81
Previous Close 4.73
Day's Range 4.48 - 4.73
52-Week Range 3.10 - 9.64
Beta n/a
Analysts Buy
Price Target 10.84 (+137.2%)
Earnings Date n/a

About MAIA

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2022
Employees 9
Stock Exchange NYSEAMERICAN
Ticker Symbol MAIA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MAIA stock is "Buy." The 12-month stock price forecast is $10.84, which is an increase of 137.20% from the latest price.

Price Target
$10.84
(137.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MAIA Biotechnology Advances New Telomere-Targeting Molecule Program

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”). MAIA is designing and evaluating m...

2 weeks ago - Business Wire

MAIA Biotechnology to Participate in Four Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences a...

1 month ago - Business Wire

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food...

1 month ago - Business Wire

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), announced today that regulatory authorities in three European countries, Hungary, Poland, and Bulgar...

1 month ago - Business Wire

MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology...

2 months ago - Business Wire

MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ann...

2 months ago - Business Wire

MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today repo...

3 months ago - Business Wire

MAIA Biotechnology: Invitation to The ThinkEquity Conference

Chicago, Illinois--(Newsfile Corp. - October 12, 2022) - MAIA Biotechnology (NYSE: MAIA), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, wil...

4 months ago - Newsfile Corp

MAIA Biotechnology to Participate in ThinkEquity Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...

4 months ago - Business Wire

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...

4 months ago - Business Wire

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...

5 months ago - Business Wire

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today annou...

5 months ago - Business Wire

MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), today announced that it has been...

5 months ago - Business Wire

MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today repo...

6 months ago - Business Wire

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology d...

6 months ago - Business Wire

MAIA Biotechnology Announces Closing of Initial Public Offering

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...

6 months ago - Business Wire

Why Is MAIA Biotechnology (MAIA) Stock Soaring 15% Higher Today?

MAIA Biotechnology (NYSE: MAIA), which began trading on Thursday following its initial public offering, is climbing sharply this morning. In mid-morning trading, MAIA stock jumped 15% to $6.66.

6 months ago - InvestorPlace

MAIA Biotechnology Announces Pricing of Initial Public Offering

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...

6 months ago - Business Wire